Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects

Candace Y W Lee, Horng Haur Chen, Ondrej Lisy, Suzanne Swan, Courtney Cannon, Hsiao D. Lieu, John C Jr. Burnett

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.

Original languageEnglish (US)
Pages (from-to)668-673
Number of pages6
JournalJournal of Clinical Pharmacology
Volume49
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Natriuretic Peptides
Healthy Volunteers
Clinical Trials
C-Type Natriuretic Peptide
Hypotension
Kidney
Amino Acids
Cyclic GMP
Aldosterone
Heart Failure
Blood Pressure
Ligands
Peptides

Keywords

  • C-type natriuretic peptide
  • CD-NP
  • Chimeric natriuretic peptide
  • Dendroaspis natriuretic peptide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. / Lee, Candace Y W; Chen, Horng Haur; Lisy, Ondrej; Swan, Suzanne; Cannon, Courtney; Lieu, Hsiao D.; Burnett, John C Jr.

In: Journal of Clinical Pharmacology, Vol. 49, No. 6, 06.2009, p. 668-673.

Research output: Contribution to journalArticle

Lee, Candace Y W ; Chen, Horng Haur ; Lisy, Ondrej ; Swan, Suzanne ; Cannon, Courtney ; Lieu, Hsiao D. ; Burnett, John C Jr. / Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. In: Journal of Clinical Pharmacology. 2009 ; Vol. 49, No. 6. pp. 668-673.
@article{b8d638f7e222410ca41abf13364638b4,
title = "Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects",
abstract = "CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.",
keywords = "C-type natriuretic peptide, CD-NP, Chimeric natriuretic peptide, Dendroaspis natriuretic peptide",
author = "Lee, {Candace Y W} and Chen, {Horng Haur} and Ondrej Lisy and Suzanne Swan and Courtney Cannon and Lieu, {Hsiao D.} and Burnett, {John C Jr.}",
year = "2009",
month = "6",
doi = "10.1177/0091270009336233",
language = "English (US)",
volume = "49",
pages = "668--673",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects

AU - Lee, Candace Y W

AU - Chen, Horng Haur

AU - Lisy, Ondrej

AU - Swan, Suzanne

AU - Cannon, Courtney

AU - Lieu, Hsiao D.

AU - Burnett, John C Jr.

PY - 2009/6

Y1 - 2009/6

N2 - CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.

AB - CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.

KW - C-type natriuretic peptide

KW - CD-NP

KW - Chimeric natriuretic peptide

KW - Dendroaspis natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=67149084605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149084605&partnerID=8YFLogxK

U2 - 10.1177/0091270009336233

DO - 10.1177/0091270009336233

M3 - Article

C2 - 19395584

AN - SCOPUS:67149084605

VL - 49

SP - 668

EP - 673

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 6

ER -